Patents by Inventor Stefan Ewert
Stefan Ewert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160185850Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: March 8, 2016Publication date: June 30, 2016Inventors: Stefan Ewert, David Urech, Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
-
Patent number: 9315572Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: February 20, 2014Date of Patent: April 19, 2016Assignee: ESBATech, an Alcon Biomedical Research, Unit LLCInventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Patent number: 9273126Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.Type: GrantFiled: November 2, 2012Date of Patent: March 1, 2016Assignees: Delenex Therapeutics AG, University of ZurichInventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
-
Publication number: 20150057191Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.Type: ApplicationFiled: August 26, 2014Publication date: February 26, 2015Inventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
-
Patent number: 8853362Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.Type: GrantFiled: May 21, 2003Date of Patent: October 7, 2014Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
-
Publication number: 20140171634Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: February 20, 2014Publication date: June 19, 2014Applicant: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Patent number: 8691228Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: December 7, 2012Date of Patent: April 8, 2014Assignee: ESBATech, an Alcon Biomedical Research Unit LLCInventors: Stefan Ewert, Alcide Barberis, David Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Publication number: 20130345292Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.Type: ApplicationFiled: November 2, 2012Publication date: December 26, 2013Inventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
-
Patent number: 8400098Abstract: A method for controlling the movement of axles whose drives are connected for exchanging energy, in particular by connecting intermediate circuits of the converters respectively comprised by the drives, prior to the start of the movement, a predictive determination of the sequence of movements being performed, in the process of which first the time-critical axle is determined, then the travel profile of the time-critical axle is defined, then a respective total energy consumption is assigned to the possible travel profiles of additional axles, from these, the profile is selected that has the smallest total energy requirement associated with it, and then the movement is carried out.Type: GrantFiled: August 27, 2007Date of Patent: March 19, 2013Assignee: Sew-Eurodrive GmbH & Co. KGInventors: Stefan Ewert, Andreas Steinsdörfer
-
Patent number: 8389693Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: September 26, 2011Date of Patent: March 5, 2013Assignee: ESBATech, an Alcon Boimedical Research Unit, LLCInventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Patent number: 8323647Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerization of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.Type: GrantFiled: September 15, 2008Date of Patent: December 4, 2012Assignees: Delenex Therapeutics AG, University of ZurichInventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
-
Publication number: 20120064077Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: September 26, 2011Publication date: March 15, 2012Applicant: ESBATECH, AN ALCON BIOMEDICAL RESEARCH UNIT LLC.Inventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Patent number: 8067547Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: June 6, 2006Date of Patent: November 29, 2011Assignee: ESBATech, an Alcon Biomedical Research Unit, LLCInventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Publication number: 20110020220Abstract: The invention discloses an isolated antibody that selectively binds to the C-terminal part of Abeta and is humanized or fully human. The antibody of the invention is capable of preventing oligomerisation of Abeta. Furthermore, a method of diagnosis comprising the steps of: (i) Labelling an antibody; (ii) Administering an effective dose of said antibody intranasally or systemically to a subject; and (iii) Detecting the concentration and/or presence of the labelled antibody in body parts of the subject is disclosed.Type: ApplicationFiled: September 15, 2008Publication date: January 27, 2011Applicants: Delenex Therapeutics AG, University of Zurich Prorektorat ForschungInventors: Stefan Ewert, Adrian Auf Der Maur, Susann Cattepoel, Roger Nitsch
-
Publication number: 20100322930Abstract: The invention provides fibronectin-based binding molecules and methods for introducing donor CDRs into a fibronectin-based binding scaffold, in particular, Fn3. The fibronectin-based binding molecules of the invention may be further conjugated to another moiety, for example, Fc, anti-FcRn, HSA, anti-HSA, and PEG, for improved half life and stability, particularly in mammalian cells. The invention also provides methods for screening such molecules for binding to a target antigen as well as the manufacture and purification of a candidate binder.Type: ApplicationFiled: December 22, 2008Publication date: December 23, 2010Inventors: Frank Kolbinger, Karen Jane Vincent, Barbara Brannetti, Stefan Ewert
-
Publication number: 20100113355Abstract: An scFv peptide comprising a VH domain and a VL domain linked by an amino acid spacer is disclosed. The VH domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 64. The VL domain comprises a sequence with at least 80% sequence identity to the sequence of SEQ ID NO. 66. The scFv peptide comprises an additional feature selected from (a) to (e) and combinations thereof. (a) A substitution or deletion of an amino acid in the VH domain at a position corresponding to that selected from the group consisting of: I29, H68, N85, C97 and combinations thereof. (b) A substitution or deletion of an amino acid in the VL domain at a position corresponding to that selected from the group consisting of: V2, V3, F10, F14, A39, N76 and combinations thereof. (c) The amino acid spacer comprises the sequence (GGGGS)n wherein n is between 4 and 6. (d) The VH domain further comprises an N-terminal pelB signal sequence comprising the sequence of SEQ ID NO.Type: ApplicationFiled: April 24, 2006Publication date: May 6, 2010Inventors: Naresh Chennamsetty, Stefan Ewert, Bernard Helk, Bernhardt Trout, Philipp Wechner
-
Publication number: 20100007302Abstract: A method for controlling the movement of axles whose drives are connected for exchanging energy, in particular by connecting intermediate circuits of the converters respectively comprised by the drives, prior to the start of the movement, a predictive determination of the sequence of movements being performed, in the process of which first the time-critical axle is determined, then the travel profile of the time-critical axle is defined, then a respective total energy consumption is assigned to the possible travel profiles of additional axles, from these, the profile is selected that has the smallest total energy requirement associated with it, and then the movement is carried out.Type: ApplicationFiled: August 27, 2007Publication date: January 14, 2010Applicant: Sew-Eurodrive GmbH & Co. KGInventors: Stefan Ewert, Andreas Steinsdörfer
-
Publication number: 20090263382Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: ApplicationFiled: June 6, 2006Publication date: October 22, 2009Applicant: ESBATechInventors: Stefan Ewert, Alcide Barberis, David M. Urech, Adrian Auf Der Maur, Peter Lichtlen
-
Publication number: 20060127893Abstract: The present invention relates to a method for the optimization of isolated human immunoglobulin variable heavy (VH) and light (VL) constructs.Type: ApplicationFiled: July 19, 2002Publication date: June 15, 2006Inventors: Stefan Ewert, Thomas Huber, Annemarie Honegger, Andreas Pluckthun
-
Publication number: 20060035320Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.Type: ApplicationFiled: May 21, 2004Publication date: February 16, 2006Inventors: Kathrin Tissot, Stefan Ewert, Adrian Maur, Alcide Barberis, Dorminik Escher